Tandem Diabetes Care | TNDM - Selling And Administration Expenses


Tandem Diabetes Care reported $99.86M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.27B 138M Mar/2026
Accuray USD 124.78M 2.54M Dec/2025
Align Technology USD 465.34M 23.67M Mar/2026
AtriCure USD 84.55M 6.21M Mar/2026
Baxter International USD 728M 33M Mar/2026
Becton, Dickinson and Co. USD 1.21B 180M Mar/2026
Boston Scientific USD 1.78B 53M Mar/2026
Cooper Companies USD 676.2M 303.1M Mar/2026
Dexcom USD 349.7M 49.8M Mar/2026
Edwards Lifesciences USD 522.2M 80.7M Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Globus Medical USD 297.77M 20.7M Mar/2026
ICU Medical USD 155.81M 3.04M Dec/2025
Inogen USD 43.77M 510K Jun/2024
Insulet USD 317.2M 14.2M Mar/2026
Integra LifeSciences USD 178.24M 21.79M Mar/2026
Intuitive Surgical USD 613.3M 73.8M Mar/2026
J&J USD 6.42B 381M Jun/2026
Medtronic 2.96B 9M Dec/2025
Merit Medical Systems USD 110.47M 4.36M Mar/2026
Orthofix International USD 130.35M 11.31M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Stryker USD 2.15B 17M Mar/2026
Tandem Diabetes Care USD 99.86M 5.34M Dec/2025
Teleflex USD 226.01M 3.64M Mar/2026
Zimmer Biomet Holdings USD 849.9M 5.8M Mar/2026